Abstract 1218P
Background
Cancer is considered a leading cause of mortality and morbidity worldwide. This study constitutes one part of the user requirement definition of INCISIVE EU project. The project has been designed to explore the full potential of artificial intelligence (AI)-based technologies in cancer imaging. The study aimed to map cancer care pathways (breast, prostate, colorectal and lung cancers) across INCISIVE partner countries, and identify obstacles within these pathways.
Methods
A qualitative research approach employing email interviews was used. A purposive sampling strategy was employed to recruit ten oncology specialised healthcare professionals from INCISIVE partner countries: Greece, Cyprus, Spain, Italy, Finland, United Kingdom (UK) and Serbia. Data was collected between December 2020 and April 2021. Data was entered into Microsoft Excel spreadsheet to allow content and comparative analysis. Appropriate ethical approval was obtained for this study.
Results
Delays in the diagnosis and treatment of cancer was evident from all the pathways studied. With the exception of the UK, none of the countries studied had official national data regarding delays in cancer diagnosis and treatment. There was a considerable variation in the availability of imaging and diagnostic services across the seven countries that were analysed. Several concerns were also noted for national screening for the four investigated cancer types.
Conclusions
Delays in the diagnosis and treatment of cancer remain challenging issues that need to be addressed. To effectively address these challenges, it is crucial to have a systematic reporting of diagnostic and therapeutic delays in all countries. Proper estimation of the magnitude of the problem is essential, as no problem can be effectively tackled without an accurate understanding of its magnitude. Our findings also support the orientation of the current policies towards early detection and wide scale adoption and implementation of cancer screening, through research, innovation, and technology. Technologies involving AI can have a great potential to revolutionise cancer care delivery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
INCISIVE Consortium.
Funding
EU Horizion 2020.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1251P - Development of a deep learning algorithm for lung cancer diagnosis using methylation and fragment size profiles of cfDNA
Presenter: Jiyoung Huh
Session: Poster session 14
1252P - Quantitative cell signaling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial: Presentation of skin tumor data
Presenter: Diederick Keizer
Session: Poster session 14
1253P - Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)
Presenter: Marcel Trautmann
Session: Poster session 14
1254P - Retrospective analysis of brain OMX: Diagnostic tool for structural (T1) and functional connectome (RS-FMRI) analysis of brain
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14
1255P - Evaluating GPT-4 as an academic support tool for clinicians: A comparative analysis of case records from the literature
Presenter: Marcos Aurelio Fonseca Magalhaes Filho
Session: Poster session 14
1256P - Value of detection of peripheral blood circRNA based on digital PCR in the diagnosis of lung adenocarcinoma
Presenter: Jihong Zhou
Session: Poster session 14
1257P - Double heterozygous prevalence in hereditary cancer syndromes in Northern Mexico population
Presenter: Carlos Burciaga Flores
Session: Poster session 14
1258P - Does FDG PET-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?
Presenter: Andrea Ciarmiello
Session: Poster session 14
1260TiP - Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach
Presenter: Young-Chul Kim
Session: Poster session 14
1773P - ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
Presenter: Wanling Xie
Session: Poster session 14